Sanofi EFC 17504 LIP Non relapsing SPMS FREVIVA
STUDY AND PROTOCOL
EFC17504
STUDY DETAILS
A Phase 3 randomized, double-blind, efficacy and safety study comparing frexalimab (SAR441344) to placebo in adult participants with nonrelapsing secondary progressive multiple sclerosis
FURTHER INFORMATION
ClinicalTrials.gov Identifier: NCT06141486